Comparison of the effects of five adjuvants on the antibody response to influenza virus antigen in guinea pigs. 1995

J A Robuccio, and J W Griffith, and E A Chroscinski, and P J Cross, and T E Light, and C M Lang
Wyeth-Ayerst Laboratories, Marietta, PA 17547, USA.

Five adjuvants were tested for their effect on the immune response in guinea pigs to the hemagglutinin antigen of influenza virus strain B/Panama. Vaccines containing 924 micrograms of hemagglutinin antigen/ml were prepared at high and low doses of Freund's complete and incomplete adjuvants, Syntex adjuvant, RIBI's adjuvant, TiterMax adjuvant, and aluminum phosphate adjuvant. Responses to these vaccines were compared with those to a control vaccine containing influenza virus B/Panama hemagglutinin antigen and saline. On day 28, vaccines containing the following adjuvant doses had significantly higher titers than the titer for the control: Freund adjuvants at high and low doses, RIBI at high dose, TiterMax at high and low doses, and aluminum phosphate at high dose. On day 42, vaccines containing the following adjuvant doses had significantly higher titers than that for the control: Freund adjuvants at high and low doses, RIBI at high dose, TiterMax at high dose, and aluminum phosphate at high dose. Freund adjuvants at high and low doses, RIBI adjuvant at high dose, and aluminum phosphate at high dose caused significantly greater swelling at the inoculation site than did the control vaccine. TiterMax adjuvant at high and low doses, and aluminum phosphate at low dose caused minor swelling at the inoculation site, but it was not significantly different from the swelling caused by the control vaccine. Syntex adjuvant at high and low doses, RIBI at low dose, and control (saline/antigen) at high and low doses caused no swelling after inoculation. Overall, the high dose of adjuvants caused greater tissue swelling than did the low dose of adjuvants.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D008050 Lipid A Lipid A is the biologically active component of lipopolysaccharides. It shows strong endotoxic activity and exhibits immunogenic properties.
D008297 Male Males
D009981 Influenza B virus Species of the genus BETAINFLUENZAVIRUS that cause HUMAN INFLUENZA and other diseases primarily in humans. Antigenic variation is less extensive than in type A viruses (INFLUENZA A VIRUS) and consequently there is no basis for distinct subtypes or variants. Epidemics are less likely than with INFLUENZA A VIRUS and there have been no pandemics. Previously only found in humans, Influenza B virus has been isolated from seals which may constitute the animal reservoir from which humans are exposed. Betainfluenzavirus influenzae,FLUBV,Human Influenza B Virus,Influenza Viruses Type B,Influenza virus type B,Orthomyxoviruses Type B,Influenza B viruses
D010710 Phosphates Inorganic salts of phosphoric acid. Inorganic Phosphate,Phosphates, Inorganic,Inorganic Phosphates,Orthophosphate,Phosphate,Phosphate, Inorganic
D011060 Poloxalene A copolymer of polyethylene and polypropylene ether glycol. It is a non-ionic polyol surface-active agent used medically as a fecal softener and in cattle for prevention of bloat. Oxyethylene Oxypropylene Polymer,Polyoxyethylene Polyoxypropylene Polyoxyethylene Polymer,Bloat Guard,Poloxalene 2930,Proxanol,SK&F-18667,Tergitol,Therabloat,Oxypropylene Polymer, Oxyethylene,Polymer, Oxyethylene Oxypropylene,SK&F 18667,SK&F18667
D011136 Polysorbates Sorbitan mono-9-octadecanoate poly(oxy-1,2-ethanediyl) derivatives; complex mixtures of polyoxyethylene ethers used as emulsifiers or dispersing agents in pharmaceuticals. Polysorbate,Polysorbate 20,Polysorbate 80,Sorbitan Derivatives,Tween,Tweens,PSML,Polyoxyethylene Sorbitan Monolaurate,Tween 20,Tween 60,Tween 80,Tween 81,Tween 85,20s, Polysorbate,20s, Tween,60s, Tween,80s, Polysorbate,80s, Tween,81s, Tween,85s, Tween,Derivative, Sorbitan,Derivatives, Sorbitan,Monolaurate, Polyoxyethylene Sorbitan,Monolaurates, Polyoxyethylene Sorbitan,PSMLs,Polyoxyethylene Sorbitan Monolaurates,Polysorbate 20s,Polysorbate 80s,Sorbitan Derivative,Sorbitan Monolaurate, Polyoxyethylene,Sorbitan Monolaurates, Polyoxyethylene,Tween 20s,Tween 60s,Tween 80s,Tween 81s,Tween 85s
D003311 Cord Factors Toxic glycolipids composed of trehalose dimycolate derivatives. They are produced by MYCOBACTERIUM TUBERCULOSIS and other species of MYCOBACTERIUM. They induce cellular dysfunction in animals. Trehalose Dimycolates,Cord Factor,Trehalose-6,6'-Dimycolate,Dimycolates, Trehalose,Factor, Cord,Factors, Cord,Trehalose 6,6' Dimycolate
D005620 Freund's Adjuvant An antigen solution emulsified in mineral oil. The complete form is made up of killed, dried mycobacteria, usually M. tuberculosis, suspended in the oil phase. It is effective in stimulating cell-mediated immunity (IMMUNITY, CELLULAR) and potentiates the production of certain IMMUNOGLOBULINS in some animals. The incomplete form does not contain mycobacteria. Freund Adjuvant,Adjuvant, Freund,Adjuvant, Freund's,Freunds Adjuvant
D006168 Guinea Pigs A common name used for the genus Cavia. The most common species is Cavia porcellus which is the domesticated guinea pig used for pets and biomedical research. Cavia,Cavia porcellus,Guinea Pig,Pig, Guinea,Pigs, Guinea
D006389 Hemagglutinins, Viral Specific hemagglutinin subtypes encoded by VIRUSES. Viral Hemagglutinin,Viral Hemagglutinins,Hemagglutinin, Viral

Related Publications

J A Robuccio, and J W Griffith, and E A Chroscinski, and P J Cross, and T E Light, and C M Lang
September 1974, Infection and immunity,
J A Robuccio, and J W Griffith, and E A Chroscinski, and P J Cross, and T E Light, and C M Lang
September 1967, Acta virologica,
J A Robuccio, and J W Griffith, and E A Chroscinski, and P J Cross, and T E Light, and C M Lang
May 2021, NPJ vaccines,
J A Robuccio, and J W Griffith, and E A Chroscinski, and P J Cross, and T E Light, and C M Lang
February 2013, Research in veterinary science,
J A Robuccio, and J W Griffith, and E A Chroscinski, and P J Cross, and T E Light, and C M Lang
October 1973, Infection and immunity,
J A Robuccio, and J W Griffith, and E A Chroscinski, and P J Cross, and T E Light, and C M Lang
September 2019, Vaccine,
J A Robuccio, and J W Griffith, and E A Chroscinski, and P J Cross, and T E Light, and C M Lang
June 1980, Cancer research,
J A Robuccio, and J W Griffith, and E A Chroscinski, and P J Cross, and T E Light, and C M Lang
March 2012, Veterinary immunology and immunopathology,
J A Robuccio, and J W Griffith, and E A Chroscinski, and P J Cross, and T E Light, and C M Lang
February 1986, The Australian journal of experimental biology and medical science,
J A Robuccio, and J W Griffith, and E A Chroscinski, and P J Cross, and T E Light, and C M Lang
October 1992, AIDS research and human retroviruses,
Copied contents to your clipboard!